Anthem Biosciences Limited Earnings Summary — Q1 FY2027
Anthem Biosciences Reports Q1 FY27 Results Amid Revenue Softness and Segmental Shift
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue declined 31.5% sequentially in Q1 FY2027.
- Revenue of ₹418 Cr is 22.6% lower year-on-year.
- Revenue has compounded at 11.1% annualised over the last 10 quarters.
- Net profit of ₹120 Cr is 11.7% below the same quarter last year.
- Profit growth is outpacing revenue growth, pointing to positive operating leverage.
- Net profit has compounded at 20.7% annualised across the period.
- Operating margin stands at 36.0% in Q1 FY2027.
- Operating margin expanded by 55 bps year-on-year.
- Over the last two years operating margin has expanded by 29 bps.
- PBT margin is 34.6%.
- Expense growth of -23.2% remained below revenue growth of -22.6%.
- Operating profit of ₹151 Cr is 21.4% lower year-on-year.
- Operating leverage has been under pressure recently.
- 3 of the last 5 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 43/100 (Moderate) on the latest 10 quarters.
- Business momentum has softened and warrants monitoring.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Improving | 418 | 611 | 423 | 550 | 540 | 483 | 498 | 525 | 339 | — |
| Expenses | Improving | 268 | 344 | 266 | 332 | 349 | 288 | 338 | 330 | 218 | — |
| Operating Profit | Improving | 151 | 267 | 157 | 218 | 191 | 195 | 160 | 195 | 121 | — |
| Operating Margin | Stable | 36.0% | 43.7% | 37.1% | 39.6% | 35.5% | 40.4% | 32.0% | 37.2% | 35.7% | — |
| Other Income | Volatile | 25 | 52 | 8 | 48 | 23 | 14 | 24 | 28 | 19 | — |
| Interest | Volatile | 1 | 2 | 0 | 3 | 2 | 1 | 3 | 4 | 4 | — |
| Depreciation | Improving | 30 | 40 | 35 | 34 | 26 | 30 | 20 | 20 | 19 | — |
| Profit Before Tax | Volatile | 145 | 278 | 130 | 230 | 186 | 178 | 161 | 200 | 118 | — |
| Tax | Volatile | 25 | 88 | 38 | 56 | 50 | 96 | 37 | 38 | 36 | — |
| Net Profit | Volatile | 120 | 190 | 93 | 173 | 136 | 83 | 124 | 162 | 82 | — |
| Net Margin | Improving | 28.7% | 31.1% | 21.9% | 31.5% | 25.1% | 17.1% | 25.0% | 30.9% | 24.3% | — |
Key Takeaways
- Consolidated revenue saw a sharp decline of 22.58% YoY and 31.55% QoQ, primarily driven by a slowdown in the core CRDMO segment.
- CRDMO segment revenue fell to ₹3,408 Mn compared to ₹4,527 Mn in the same quarter last year, reflecting potential lumpiness in contract cycles.
- Speciality Ingredients segment also contracted, contributing ₹774.16 Mn vs ₹874.98 Mn YoY, a decline of approximately 11.5%.
- Operating profitability (PBT margin) declined sequentially from 45.5% in Q4 FY26 to 34.6% in the current quarter, though it remains stable YoY.
- The company issued 1.67 million new equity shares during the quarter under its ESOP Scheme 2024, slightly diluting equity capital.
- Neoanthem Lifesciences, a wholly-owned subsidiary, showed strong profitability, contributing ₹82.22 million to the consolidated bottom line.
- Standalone financials showed a steeper revenue decline than consolidated figures, suggesting the subsidiary is helping mitigate parent-level volatility.
Management Guidance
Management is focusing on expanding the commercial molecule pipeline and digitizing operations to future-proof the enterprise against global R&D cycle volatility.
Sentiment Shift
Deteriorating
Significant sequential and year-over-year declines in both revenue and profit suggest a temporary slowdown or project-based lumpiness following a strong FY26.
Outlook
The company maintains high technological barriers in RNAi and ADCs, positioning it for long-term recovery despite the current quarter's contraction in CRDMO demand.
From the Annual Report (Key Quotes)
“The assets and liabilities of the Company are often deployed interchangeably across segments... it is impractical to allocate these.”
“During the quarter, the company has allotted 1,670,909 nos of fully paid up equity shares... under ESOP Scheme 2024.”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from Anthem Biosciences Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.